亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Long-term outcomes of local resection versus surgical resection for high-risk T1 colorectal cancer: a systematic review and meta-analysis

医学 危险系数 结直肠癌 置信区间 内科学 生存分析 淋巴结 荟萃分析 比例危险模型 肿瘤科 胃肠病学 癌症 外科
作者
Yuxiang Chen,Weina Jing,Mo Chen,Zhu Wang,Junchao Wu,Jinlin Yang,Yang Li,Kai Deng
出处
期刊:Gastrointestinal Endoscopy [Elsevier BV]
卷期号:97 (6): 1016-1030.e14 被引量:19
标识
DOI:10.1016/j.gie.2023.02.027
摘要

Patients with T1 colorectal cancer (CRC) are at high risk for lymph node metastasis and recurrence after local resection (LR) and need surgical resection (SR) for additional lymph node dissection to improve prognosis. However, the net benefits of SR and LR are still unquantified.We conducted a systematic search for studies in which survival analysis among high-risk T1 CRC patients undergoing LR and SR was performed. Overall survival (OS), recurrence-free survival (RFS), and disease-specific survival (DSS) data were extracted. Hazard ratios (HRs) and fitted survival curves for OS, RFS, and DSS were used to estimate the long-term clinical outcomes of patients in the 2 groups.This meta-analysis included 12 studies. Compared with those in the SR group, patients in the LR group had higher risks of death (HR, 2.06; 95% confidence interval [CI], 1.59-2.65), recurrence (HR, 3.51; 95% CI, 2.51-4.93), and cancer-related mortality (HR, 2.31; 95% CI, 1.17-4.54) in the long term. Fitted survival curves for the LR and SR groups revealed the 5-year, 10-year, and 20-year rates for OS (86.3% and 94.5%, 72.9% and 84.4%, and 61.8% and 71.1%), RFS (89.9% and 96.9%, 83.3% and 93.9%, and 29.6% and 90.8%), and DSS (96.7% and 98.3%, 86.9% and 97.1%, and 86.9% and 96.4%). Log-rank tests showed significant differences among all outcomes except 5-year DSS.For high-risk T1 CRC patients, the net benefit of DSS appears to be significant when the observation period exceeds 10 years. A long-term net benefit may exist but may not be applicable to all patients, especially high-risk patients with comorbidities. Therefore, LR may be a reasonable alternative for individualized treatment for some high-risk T1 CRC patients.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
磐xst完成签到 ,获得积分10
7秒前
11秒前
yuanquaner完成签到,获得积分10
29秒前
慕青应助mellow采纳,获得10
32秒前
GXY完成签到,获得积分10
37秒前
51秒前
mellow发布了新的文献求助10
55秒前
星辰大海应助自信书竹采纳,获得10
56秒前
张潘完成签到 ,获得积分10
1分钟前
李健的小迷弟应助Kevin采纳,获得10
1分钟前
1分钟前
lyy发布了新的文献求助10
1分钟前
mellow完成签到,获得积分10
1分钟前
哔哩哔哩哔哔哔完成签到,获得积分10
1分钟前
慕青应助哔哩哔哩哔哔哔采纳,获得200
1分钟前
1分钟前
1分钟前
莫提斯完成签到,获得积分20
1分钟前
CodeCraft应助星火燎原采纳,获得10
1分钟前
2分钟前
vvan发布了新的文献求助10
2分钟前
星火燎原发布了新的文献求助10
2分钟前
星火燎原完成签到,获得积分10
2分钟前
2分钟前
Mic应助幽默身影采纳,获得30
2分钟前
李爱国应助Brendan采纳,获得10
2分钟前
2分钟前
Yuuuan完成签到,获得积分10
2分钟前
遥感小虫完成签到,获得积分10
3分钟前
遥感小虫发布了新的文献求助30
3分钟前
vvan发布了新的文献求助10
3分钟前
俊秀的梦竹完成签到 ,获得积分10
3分钟前
4分钟前
4分钟前
天天快乐应助HAG采纳,获得10
4分钟前
4分钟前
蜜蜜发布了新的文献求助10
4分钟前
小马甲应助科研通管家采纳,获得10
4分钟前
脑洞疼应助科研通管家采纳,获得10
4分钟前
4分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Picture this! Including first nations fiction picture books in school library collections 2000
The Cambridge History of China: Volume 4, Sui and T'ang China, 589–906 AD, Part Two 1500
Cowries - A Guide to the Gastropod Family Cypraeidae 1200
Quality by Design - An Indispensable Approach to Accelerate Biopharmaceutical Product Development 800
Signals, Systems, and Signal Processing 610
The Oxford Handbook of Archaeology and Language 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 物理 内科学 复合材料 催化作用 物理化学 光电子学 电极 细胞生物学 基因 无机化学
热门帖子
关注 科研通微信公众号,转发送积分 6394441
求助须知:如何正确求助?哪些是违规求助? 8209627
关于积分的说明 17382127
捐赠科研通 5447567
什么是DOI,文献DOI怎么找? 2880008
邀请新用户注册赠送积分活动 1856463
关于科研通互助平台的介绍 1699118